Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data.
Singer
Jack W
JW
Cell Therapeutic, Inc., 201 Elliott Avenue West, Suite 400, Seattle, Washington 98119, USA. jsinger@ctiseattle.com
Baker
Brian
B
De Vries
Peter
P
Kumar
Anil
A
Shaffer
Scott
S
Vawter
Ed
E
Bolton
Mary
M
Garzone
Pamela
P
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D002986:Clinical Trials as Topic; D006801:Humans; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D011099:Polyglutamic Acid / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000031:analogs & derivatives; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D011099:Polyglutamic Acid; D017239:Paclitaxel; C509139:paclitaxel poliglumex